BMSSC
VKTX icon

B. Metzler seel. Sohn & Co’s Viking Therapeutics VKTX Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,857
Closed -$221K – 777
2023
Q4 		$221K Buy
+11,857
New +$155K ﹤0.01% 736
2023
Q3 		– Sell
-13,882
Closed -$225K – 753
2023
Q2 		$225K Buy
+13,882
New +$291K ﹤0.01% 692

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

B. Metzler seel. Sohn & Co's VKTX Position: Q1 2024 in Review

B. Metzler seel. Sohn & Co sold out of Viking Therapeutics (VKTX) in Q1 2024, closing a stake of 11,857 shares — an estimated $221K sold.

B. Metzler seel. Sohn & Co first reported a position in VKTX in Q2 2023 and held it in 2 quarters. The position peaked at $225K in Q2 2023. 375 funds tracked by Wall St. Rank hold VKTX as of Q1 2024.

  • B. Metzler seel. Sohn & Co reported no remaining Viking Therapeutics position as of Q1 2024 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 11,857 Viking Therapeutics shares in Q1 2024, an estimated $221K.
  • B. Metzler seel. Sohn & Co first reported a position in Viking Therapeutics in Q2 2023 and held it in 2 quarters.
  • B. Metzler seel. Sohn & Co's Viking Therapeutics position peaked at $225K in Q2 2023.
  • 375 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2024.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2024, filed 15 May 2024.